Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.

Autor: Schenk KM; Department of Oncology, Bozeman Health Deaconess Cancer Center, Bozeman, MT.; Department of Oncology, Johns Hopkins University, Baltimore, MD., Deutsch JS; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD., Chandra S; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Davar D; Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA., Eroglu Z; Department of Cutaneous Oncology, The Moffitt Cancer Center and Research Institute, Tampa, FL., Khushalani NI; Department of Cutaneous Oncology, The Moffitt Cancer Center and Research Institute, Tampa, FL., Luke JJ; Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA., Ott PA; Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA., Sosman JA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Aggarwal V; Division of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL., Schollenberger MD; Department of Oncology, Johns Hopkins University, Baltimore, MD., Sharfman WH; Department of Oncology, Johns Hopkins University, Baltimore, MD.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD., Bibee KP; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD., Scott JF; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD.; Clinical Skin Center of Northern Virginia, Fairfax, VA., Loss MJ; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD., Wang H; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Division of Quantitative Sciences, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD., Qi H; Division of Quantitative Sciences, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD., Sharon E; National Cancer Institute, Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD., Streicher H; National Cancer Institute, Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD., Chen HX; National Cancer Institute, Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD., Woodward RN; CareDx, Brisbane, CA., Bagnasco SM; Department of Pathology, Johns Hopkins University School of Medicine and Johns Hopkins Hospital, Baltimore, MD., Taube JM; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD., Topalian SL; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD., Brennan DC; Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD., Lipson EJ; Department of Oncology, Johns Hopkins University, Baltimore, MD.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Mar 20; Vol. 42 (9), pp. 1011-1020. Date of Electronic Publication: 2024 Jan 22.